Home

MARKSMAN HEALTHCARE COMMUNICATIONS | A DATA SCIENCE COMPANY

In this progressing and increasingly competitive commercial landscape, attaining optimal market access is becoming extra challenging for pharmaceutical/medical device patrons. In the stir of the global economic crisis, ever increasing costs and abating healthcare budgets, payers have a significant and growing influence on a product’s commercial success. The need to demonstrate clinical and economic evidence of a product to providers, healthcare decision-makers and payers is becoming the central component to a product’s success.

MarksMan Healthcare Communications is a HEOR, scientific outsourcing and research consulting, committed in providing the highest level of scientific evidence to optimize the value and health impact of medicines and health technologies. We offer customised information solutions for all stages of product’s life-cycle and therapeutic categories. We utilize the expertise of our trained professionals to provide accurate, consistent and concise product, disease and therapeutic area information.

Our experienced and trained analytics team provides HEOR, RWE and market access support to large and small life science companies. We also provide services pertaining to
“Scientific Writing, Medical Information, and Healthcare Analytics”

OUR SERVICES

A scientific research consulting committed in providing the highest level of scientific evidence to optimize the value and health impact of medicines and health technologies. We offer customised information solutions for all stages of product’s life-cycle and therapeutic categories.

HEOR

Medical Affairs

Data Curation

Patient Registry

Data Analytics

LATEST FROM BLOG

18Jan 2019

Drug prices in the US are the highest in the world, which necessitate new or alternate payment approaches. For instance, the new treatments for hepatitis C virus (HCV) infection are highly effective and very expensive at the same time, at least from the view of many payers, physicians, and patients. Even 5 years after these […]

12Jan 2019

Today’s era of risk based, precision and personalized medicine demands clinical prediction models. Prediction modelling studies focus on two kinds of outcomes, viz. diagnosis (probability of a condition that is undetected) and prognosis (probability of developing a certain outcome in the future). (1,2) These studies develop, validate, or update a multivariable prediction model, wherein multiple […]

29Dec 2018

Clinical trials lay the foundation for the biomedical research enterprise. They not only assess the applicability of innovative laboratory findings in humans, but also generate robust evidence on treatments and/or preventive interventions in routine clinical care. Clinical trials also directly engage human participants, who trust the investigators to maintain utmost scientific as well as ethical […]

LATEST PRESENTATIONS

  • ISPOR 23rd Annual Meeting, May 19-23, 2018, Baltimore, USA

    Efficacy and Safety of Everolimus as a Combination Therapy in the Treatment of Metastatic Breast Cancer: A Systemic Review and Meta-analysis

  • ISPOR 23rd Annual Meeting, May 19-23, 2018, Baltimore, USA

    Efficacy and Safety of Vedolizumab in the Treatment of Ulcerative Colitis: A Systemic Review and Meta-analysis

  • DIA 2018 Global Annual Meeting 2018, June 24-28, 2018, Boston, USA

    Role of Social Media in Patient Reported Outcomes (PRO) Research

  • ISPOR 23rd Annual Meeting, May 19-23, 2018, Baltimore, USA

    Efficacy and Safety of Enzalutamide in Metastatic Prostate Cancer Patients: A Systematic Review and Meta-Analysis

  • ISPOR 23rd Annual Meeting, May 19-23, 2018, Baltimore, USA

    Adaptive Licensing and Real World Evidence (RWE)

  • ISPOR 23rd Annual Meeting, May 19-23, 2018, Baltimore, USA

    A Comparison of AMSTAR and ROBIS tools for Methodological Quality Assessment of Systematic reviews of Alzheimer’s Disease

WHAT OUR CLIENT SAY

OUR COLLABORATIONS